Figure 9.

Sex-specific drug-induced arrhythmogenic risk assessment. Male (Upper) and female (Lower) drug-induced arrhythmogenic risk assessment for dofetilide, a high risk drug, chlorpromazine, an intermediate risk drug, and diltiazem, a low risk drug. The color-coded line represents drug-specific concentration-dependent I_CaL/I_Kr ion channel blocking trajectory, normalized with respect to the drug's effective free therapeutic plasma concentration. The gray diamond shaped marker highlights the critical concentration, annotated in the plot's bottom corner, at which the drug's block-concentration trajectory crosses the mean multi-fidelity arrhythmogenicity classification boundary.